IUGR; Cause and Relationship

Sponsor
Karolinska Institutet (Other)
Overall Status
Completed
CT.gov ID
NCT05142644
Collaborator
(none)
80,000
1
21.9
3645.2

Study Details

Study Description

Brief Summary

Intrauterine growth restriction (IUGR) is a pregnancy complication in about 3-5% of all pregnancies in Sweden. IUGR fetuses are at high risk of morbidity and death. The method used in Sweden to detect IUGR is repeated measurements of pregnant women's symphysis-fundus measure (SF measure).

Weight estimation with ultrasound is performed only on indication; stagnant or deplaning SF dimensions or in the event of complications. Only high-risk pregnancies have repeated growth checks during pregnancy from the beginning.

There are potential benefits to detecting IUGR fetuses during pregnancy. Still, the effect is questioned. A meta-analysis of randomized studies could not benefit from a routine ultrasound in the third trimester.

The scientific purpose of this work is to evaluate the benefits of early detection and care of SGA (small for gestational age)/IUGR (growth-inhibited) fetuses and, if possible, to increase knowledge about this patient group. The hope is that this will lead to a better opportunity to personalize both preventive care and treatment of these women and children.

Condition or Disease Intervention/Treatment Phase
  • Procedure: ultrasound

Detailed Description

Design: Register-based cohort study. Population: All pregnancies in Stockholm from 2014 to 2017 A Composite outcome for the study is constructed and consists of at least one of the following outcomes

  1. HIE (hypoxic-ischemic encephalopathy)2-3 (neonatal convulsions in the fetus after childbirth),

  2. Intracranial hemorrhage,

  3. Apgar score < 4 at 5 minutes,

  4. Arterial umbilical cord pH (potential of hydrogen) < 7.10,

  5. Intrauterine fetal death, 6)intrapartal death.

Inclusion: All pregnancies in Stockholm with a fetus, born between 2014 and 2017 and without chromosomal abnormalities or other structural abnormalities, will be included in the project.

Study Design

Study Type:
Observational
Actual Enrollment :
80000 participants
Observational Model:
Cohort
Time Perspective:
Retrospective
Official Title:
Intra Uterine Growth Retardation;Causes and Relationship
Actual Study Start Date :
Jan 1, 2020
Actual Primary Completion Date :
Oct 30, 2021
Actual Study Completion Date :
Oct 30, 2021

Arms and Interventions

Arm Intervention/Treatment
Early / growth restriction

Intrauterine growth restriction with onset before 32 weeks of gestation

Procedure: ultrasound
An extra ultrasound performed during pregnancy

Late growth restriction

Intrauterine growth restriction with onset after 32 weeks of gestation

Procedure: ultrasound
An extra ultrasound performed during pregnancy

Outcome Measures

Primary Outcome Measures

  1. The frequency of newborns with an affected perinatal outcome (low Apgar score and or affected acid-base status at labor) [2014-2017]

    Will the perinatal outcome at delivery( be measured as a low Apgar score at 5 minutes or an affected acid-base status in cord blood) be improved if IUGR(intrauterine growth restriction) is identified before labor

Secondary Outcome Measures

  1. The frequency of newborns with an affected perinatal outcome (low Apgar score and or affected acid-base status at labor)(2) [January 1th 2014- december 31th 2017]

    Will the outcome changes persist if the group with IUGR will be divided into early- or late-diagnosed IUGR (before and after week 32 of pregnancy)?

Eligibility Criteria

Criteria

Ages Eligible for Study:
N/A and Older
Sexes Eligible for Study:
Female
Inclusion Criteria:
  • All pregnancies in Stockholm with a fetus, born between 2014 and 2017 and without chromosomal abnormalities or other serious structural abnormalities, will be included in the project.
Exclusion Criteria:
  • Pregnancies with known chromosomal abnormalities or other serious structural abnormalities

Contacts and Locations

Locations

Site City State Country Postal Code
1 Eva Wiberg-Itzel Stockholm Sweden 18239

Sponsors and Collaborators

  • Karolinska Institutet

Investigators

  • Principal Investigator: Eva Wiberg-Itzel, PhD, Karolinska Institute Sodersjukhuset Sweden

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Eva Wiberg-Itzel, Associate professor, Karolinska Institutet
ClinicalTrials.gov Identifier:
NCT05142644
Other Study ID Numbers:
  • Early or late IUGR
First Posted:
Dec 2, 2021
Last Update Posted:
Jan 4, 2022
Last Verified:
Dec 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Eva Wiberg-Itzel, Associate professor, Karolinska Institutet
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jan 4, 2022